Whitehawk Therapeutics, Inc. (WHWK)

Whitehawk Therapeutics, Inc. (WHWK) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $194M; returns 1 day -1.2%, 1 week +11.1%, 1 year +31.0%.

Whitehawk Therapeutics, Inc. (WHWK) is a clinical-stage oncology company focused on developing antibody-drug conjugates (ADCs) for cancer treatment. Formerly Aadi Bioscience, the company rebranded in March 2025 to reflect its strategic pivot towards ADC therapies. Whitehawk's ADC portfolio consists of three assets in-licensed from WuXi Biologics: HWK-007, HWK-016, and HWK-206.

Groups WHWK belongs to

• Antibody-Drug Conjugates
• Oncology
• Biotechnology
• Clinical Stage Biotech
• Healthcare
• Biopharmaceutical
• Cancer Therapeutics
• Clinical Stage
• Antibody Therapeutics
• Strategic Pivot

WHWK financial model: income statement, cash flow and balance sheet